Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 1
Abstract
Objective. To evaluate the survival benefit of multimodal therapy for the treatment of HCC. Background. Orthotopic liver transplantation (OLT) is considered the treatment of choice for selected patients with hepatocellular carcinoma (HCC). However, donor organ shortages and patients whose HCCs exceed OLT criteria require consideration of alternate therapeutic options such as hepatic resection, radiofrequency ablation (RFA), ethanol injection (EI), transarterial chemoembolization (TACE), and chemotherapy (CTX). This study was performed to evaluate the survival benefit of multimodal therapy for treatment of HCC as complementary therapy to OLT. Methods. A retrospective review was conducted of HCC patients undergoing therapy following multidisciplinary review at our institution from 1996 . 2006 with a minimum of a 2 year patient follow-up. Data were available on 247/252 patients evaluated. Relevant factors at time of diagnosis included symptoms, hepatitis B (HBV) and C (HCV) status, antiviral therapy, Child-Pugh classification, portal vein patency, and TNM staging. Patients underwent primary treatment by hepatic resection, RFA, EI, TACE, CTX, or were observed (best medical management). Patients with persistent or recurrent disease following initial therapy were assessed for salvage therapy. Survival curves and pairwise multiple comparisons were calculated using standard statistical methods. Results. Mean overall survival was 76.8 months. Pairwise comparisons revealed significant mean survival benefits with hepatic resection (93.2 months), RFA (66.2 months), and EI (81.1 months), compared with TACE (47.4 months), CTX (24.9 months), or observation (31.4 months). Shorter survival was associated with symptoms, portal vein thrombus, or Child-Pugh class B or C. HCV infection was associated with significantly shorter survival compared with HBV infection. Antiviral therapy was associated with significantly improved survival in chronic HBV and HCV patients only with earlier stage disease. Conclusion. Multimodal therapy is effective therapy for HCC and may be used as complementary treatment to OLT.
Authors and Affiliations
P. Andrew Schumacher, James Powell , Andrea MacNeill, Andrzej Buczkowski, Siegfried Erb, Stephen Ho, Charles Scudamore, Urs Steinbrecher, Alan Weiss, Eric Yoshida
Keywords
Related Articles
- EP ID EP77906
- DOI -
- Views 123
- Downloads 0
Effect of ezetimibe in HCV viral load after liver transplantation
Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease
Introduction. Alcoholic cirrhosis is one of the most common indications for liver transplantation (LT) inwestern countries. A major concern about transplant patients due to alcoholic liver disease (ALD) is alcoholic reci...
Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
The effect of interferon alfa against hepatitis C virus has been well documented. However, clinical efficacy is low due to the short interferon residence in the body. To prolong half-life, interferon molecules have been...
Skin manifestations of liver diseases
Autoimmune liver disorders and small-vessel vasculitis: four case reports and review of the literature
Autoimmune liver diseases (AILD) are a group of immunologically induced hepatic disorders that can lead to liver cirrhosis and end-stage liver disease. Extra-hepatic involvement and association with rheumatic diseases (s...